¡ÒÃãªé warfarin
¡ÒÃàÃÔèÁÂÒ ————————————————————————— ¡Ã³ÕÃÑ¡ÉÒẺäÁèàÃè§´èǹ ´Ù ÍÒÂØ âäÃèÇÁ ãªéÂÒÍÐäúéÒ§ ÊÓËÃ麤¹ä·Âá¹Ð¹ÓãËéàÃÔèÁã¹¢¹Ò´µèÓæ ¤×Í»ÃÐÁÒ³ 3 mg/day ËÃ×Í 21 mg/week ¡àÇé¹¶éÒà»ç¹¤¹á¡èæ ÁÕ¤ÇÒÁàÊÕè§àÃ×èͧâä comorbid ÁÒ¡ ¹éÓ˹ѡµÑǹéÍ ÍÒ¨àÃÔèÁµèÓ¡ÇèÒ 3 mg/day
ËÅѧ¨Ò¡ä´éÂÒä»»ÃÐÁÒ³ 3 Çѹ ãËéÅͧà¨ÒÐ INR ¤ÃÑé§áá INR < 1.5 => à¾ÔèÁÂÒ INR 1.5-1.9 => ¤§ÂÒà·èÒà´ÔÁ INR > 2.0 => ãËéÅ´ÂÒ à¾×èÍãËé·Õè Day 7-10 ÃдѺÂÒÍÂÙè㹪èǧ 2.0-3.0 **ªèǧááÍÒ¨µéͧ PT ·Ø¡Çѹ¨¹¡ÇèÒ INR ¨Ðà¢éÒ range ¨Ò¡¹Ñé¹à¨ÒÐÊÑ»´ÒËìÅÐ 3 ¤ÃÑé§ÍÕ¡ 1-2 ÊÑ»´ÒËì ¶éÒ¤§·ÕèáÅéÇÍÒ¨à¨Òзء 4 ÊÑ»´ÒËì ¨Ó§èÒÂæ ÇèÒ “·Ø¡Çѹ (¨¹à¢éÒ range) -> ÇѹàÇé¹Çѹ (1-2 ÊÑ»´ÒËì) -> ·Ø¡ÊÑ»´ÒËì -> ·Ø¡à´×͹" > ¼Ùé»èǤÇÃä´éÃѺ¡ÒõÃǨ INR ËÅѧàÃÔèÁÂÒ 3 Çѹ > ¼Ùé»èǤÇÃä´éÃѺ¡ÒõÃǨ INR «éÓã¹ 1 ÊÑ»´ÒËìËÅѧ»ÃѺÂÒ > ¶éÒà»éÒ¤§·ÕèáÅéÇãËé F/U at least ·Ø¡ 4 ÊÑ»´ÒËì > ¶éÒ INR äÁè¤èͤ§·Õè F/U at least ·Ø¡ 2 ÊÑ»´ÒËì àÁ×èÍàÃÔèÁÂÒáÅéǵéͧ advice, patient education ãËé´Õ **¡Ã³Õ·Õèµéͧ¡ÒüšÒÃÃÑ¡ÉÒàÃçÇ ãËé heparin ¡è͹áÅéÇ start ÂÒ¾ÃéÍÁ¡Ñ¹ ¾Í INR ä´é level áÅéÇ 2 ÇѹµÔ´¡Ñ¹¤èÍ off heparin (Bridging) ————————————————————————— ¡ÒûÃѺÂÒãËéä´é INR goal ————————————————————————— ·Ø¡¤ÃÑé§·ÕèÁÒ F/U àÃÒµéͧ´ÙÇèÒ INR ¢Í§¼Ùé»èÇÂÍÂÙèã¹ goal ËÃ×ÍäÁè? «Öè§ goal áµèÅÐâäáµèÅÐÀÒÇÐäÁèà·èҡѹ > ¶éÒ¾ºÇèÒ INR ÍÂÙè¹Í¡ goal ãËéËÒÊÒà˵ءè͹àÊÁÍ ãËé´ÙÇèÒ¡Ô¹ÂÒ¶Ù¡µéͧÊÁèÓàÊÁÍ Å×Á¡Ô¹ ËÃ×Í»ÃѺÂÒàͧ ËÃ×ÍäÁè ÁÕ drug-interaction ËÃ×ÍäÁè «×éÍÂÒÁÒ·Ò¹àͧ ¡Ò÷ҹÍÒËÒÃà»ÅÕè¹ä»ËÃ×ÍäÁè âäÃèÇÁ¢Í§¼Ùé»èÇ ¶éÒËÒà¨ÍãËé¡Ó¨Ñ´ÊÒà˵شéÇ ÍÂèÒÅ×Á¤Ô´àÃ×èͧ lab error à¾ÃÒоºä´é¹Ð > ãËé¤Ô´¢¹Ò´ÃÇÁµèÍÊÑ»´ÒËìáÅéÇ»ÃѺà»ç¹ % ËÒ¡¤èÒ INR ÍÂÙè¹Í¡à»éÒ <0.5 : »ÃѺ 5-10% weekly dose ËÒ¡¤èÒ INR ÍÂÙè¹Í¡à»éÒ >0.5-1.0 »ÃѺ 10-20% weekly dose ·Ø¡¤ÃÑé§·Õè»ÃѺÂÒãËé F/U INR 1 week (ÍÂèÒ§¹éÍ·ÕèÊØ´) ¶éÒ¤§·ÕèáÅéǤèÍ F/U q 4 weeks ————————————————————————— Warfarin overdose ÃÑ¡ÉÒÍÂèÒ§äà ————————————————————————— ¡ÒÃÃÑ¡ÉÒ¡Ã³Õ INR à¡Ô¹¨Ò¡ goal ´ÙÇèÒÁÕ major bleeding äËÁ? ¶éÒÁÕ major bleeding -> hold warfarin, ->Vit K 10 mg IV -> plus FFP â´Â vit K µéͧãËé¼èÒ¹ËÅÍ´àÅ×Í´´ÓªéÒæ <1mg/min ÍÒ¨¾Ô¨ÒóÒãËé«éÓ·Ø¡ 12 ªÑèÇâÁ§ ***VitK IV ÁÕ·Õèãªéà¾Õ§·Õèà´ÕÂǤ×Í major bleeding, any INR only! ****Vit K IV äÁè¤ÇÃãªé㹤¹ä¢é·ÕèÁÕ mechanical prosthesis
äÁèÁÕ major bleeding ãËé´Ù INR INR > 9, no bleeding : hold warfarin, Vit K 2.5-5.0 mg oral áÅÐ F/U INR ¤ÇáÅѺÁÒ»¡µÔã¹ 24-48 hours INR 5-9, no bleeding : omit 1-2 doses ËÃ×ÍãËéËÂØ´ 2 Çѹ áÅеԴµÒÁ INR ¾ÍàÃÔèÁãËÁèãËéàÃÔèÁ·ÕèµèÓŧ 20% ¨Ò¡ weekly dose à´ÔÁ ¶éÒÁջѨ¨ÑÂàÊÕè§ bleed ãËé vit K 1-2.5 mg orally
ä´é INR 4-5, no bleeding : ãËéËÂØ´ÂÒ 1 Çѹ µÔ´µÒÁ INR ¨¹à¢éÒªèǧà´ÔÁ ¾ÍàÃÔèÁãËÁèãËéàÃÔèÁ·ÕèµèÓŧ 10% ¨Ò¡ weekly dose à´ÔÁ INR 3-4, no bleeding : Å´ dose ŧ 5-10% ****ËÅÕ¡àÅÕè§¡ÒÃãªé Vitamin K ã¹ÃÒ·ÕèäÁè¨Óà»ç¹à¾ÃÒзÓãËé INR µèÓÁÒ¡ à»ç¹¡Òà reverse ÍÂèÒ§àÃçÇ áÅШзÓãËéà¡Ô´ warfarin resistance à»ç¹ÊÑ»´ÒËì¶Ö§à´×͹ àÇÅÒ¨ÐàÃÔèÁÂÒ
ãËÁè¨ÐÅÓºÒ¡ áÅÐàÊÕè§µèÍ anaphylaxis ¡Ã³ÕãËé IV ————————————————————————— Peri-operartive warfarin management ————————————————————————— à¹×èͧ¨Ò¡¡ÒÃãËéÂÒ warfarin ¨Ð·ÓãËé¼Ùé»èÇÂÁÕâÍ¡ÒÊàÊÕè§µèÍàÅ×Í´ÍÍ¡ÁÒ¡¢Öé¹ áµèã¹·Ò§¡ÅѺ¡Ñ¹¼Ùé»èǨÐä´éÃѺ¼Å»ÃÐ⪹ì¨Ò¡ÂÒã¹´éÒ¹¡Òûéͧ¡Ñ¹ Thromboembolic
phenomenon ËÃ×Í VTE ·Õè¨Ðà¡Ô´¢Öé¹ËÒ¡äÁèä´éÃѺÂÒ áµèËÒ¡¼Ùé»èǵéͧä´é¼èҵѴ¨ÐàÃÔèÁÁÕ»ÑËÒ à¾ÃÒШзÓãËéÁÕâÍ¡ÒÊàÅ×Í´ÍÍ¡§èÒÂáÅÐËÂØ´ÂÒ¡ÁÒ¡ ¼Ùé»èÇÂÍÒ¨ÁÕ major bleeding ä´éµÑé§áµè intra-op áÅÐ post-op ¶éÒà»ç¹ÍÂèÒ§¹Õé ¶ÒÁÇèÒàÃÒ¤Ç÷ÓÍÂèÒ§äôÕ? -> -> ËÂØ´ÂÒ : ¶éÒàÃÒËÂØ´ÂÒ¡è͹¼èҵѴ á¹è¹Í¹ÇèÒÃдѺ INR ÊÒÁÒöŧÁÒ»¡µÔä´é áÅШÐÁÕ¤ÇÒÁàÊÕè§àÅ×Í´ÍÍ¡¨Ò¡¡ÒüèҵѴà·èÒ¤¹·ÑèÇä» áµèÍÂèÒÅ×ÁÇèÒàÃÒ¨Ðà¾ÔèÁâÍ¡ÒÊàÊÕè§µèÍ
VTE ãËé¼Ùé»èÇÂàªè¹à´ÔÁ «Öè§â´ÂÁÒ¡áÅéÇ¡ÅØèÁ¼Ùé»èÇ·Õèä´éÃѺÂÒ warfarin ¡ç¨ÐÁÕ¤ÇÒÁàÊÕè§µèÍ TE ÁÒ¡¡ÇèÒ¤¹·ÑèÇä»ÍÂÙèáÅéÇ -> äÁè Bleed áµè stroke ¨Ó§èÒÂæ -> -> ËÂØ´ÂÒ + Bridging : ËÃ×Í¡ÒÃãªé Bridging anticoagulant ¤×Í¡ÒÃãËéËÂØ´ÂÒ warfarin áÅÐàÁ×èÍ INR < 2.0 áÅéǨ֧ãËé¡ÅØèÁ anticoagulant ·Õèà»ç¹ short-acting à¢éÒä»á·¹ àªè¹
LMWH, IV Unfractioned Heparin (UFH) «Ö觨Ðà»ç¹¡ÒÃÅ´ risk ¢Í§ TE (ÃѺªèǧµèͨҡ warfarin »ÃÐÁÒ³¹Ñé¹) áµè¨ÐÂѧÁÕ risk of bleeding ä´é -> äÁè stroke áµè bleed àÃÒ¨Ö§µéͧÁÒªÑè§ risk ¢Í§¼Ùé»èÇÂÇèÒ ÃÐËÇèÒ§ Risk TE ¡Ñº Risk Bleeding Íѹä˹àÊÕè§¡Çèҡѹ? à¾ÃÒÐáµèÅФ¹äÁèàËÁ×͹¡Ñ¹ àªè¹à´ÕÂǡѹ¡ÑºàÇÅÒàÃÒ¨ÐàÃÔèÁÂÒ warfarin 㹤¹ä¢é AF àÃÒµéͧªÑè§ÃÐËÇèÒ§ CHADSVASC áÅÐ HASBLED ãªèäËÁ¤ÃѺ àÁ×èÍäËÃè¡çµÒÁ·Õè¶éÒ Bleeding risk > TE risk ¡çäÁè¤Çà Bridge ÊÔè§·ÕèàÃÒµéͧ¨Óä´é¤×Í High TE risk ·Õè¨Ðµéͧä´éÁÒ Bridge > ¼Ùé»èÇ on Mechanical valve : mitral valve, aortic valve > ¼Ùé»èÇ AF : CHADS2 >=5, Rheumatic MS > ¼Ùé»èÇ VTE : severe thrombophilia, protein C,protein S deficiency, Antiphospholipid syndrome > ¼Ùé»èÇ recent CVA/TIA < 6 months if on mechanical valve > ¼Ùé»èÇ recent CVA/TIA < 3 months if AF or VTE *****¶éÒ¼Ùé»èÇÂÍÂÙèã¹¡ÅØèÁ¹Õé¤Ç÷ӡÒà Bridge àÊÁÍ !! ***** Bleeding Risk ¢Öé¹ÍÂÙè¡Ñºª¹Ô´ operation/procedure áºè§à»ç¹ low/intermediate/high risk ¶éÒ low risk ÊÒÁÒö¼èÒä´éâ´ÂäÁèµéͧËÂØ´ÂÒ intermediate : ãËé»ÃÖ¡ÉÒÈÑÅÂá¾·Âì high risk : µéͧËÂØ´ÂÒ Êèǹ¨Ð bridge ËÃ×ÍäÁè bridge ãËé´ÙTE risk
Procedure ·Õè low risk àªè¹ >Endoscopy, Biopsy, Endovascular intervention, PCIs >Cataract surgery, Dermatologic surgery, Dental extraction >Total knee arthroplasty, Arthroscopic surgery >Minor noncardiac surgeries Steps ¡Òà Approach ¨Ðà»ç¹¡ÒöÒÁµÑÇàͧ ´Ñ§¹Õé ¶éÒ¼Ùé»èÇè on warfarin ÍÂÙèà´ÔÁ áÅÐÂѧäÁèÁÕ·Ò§ÇèÒ¨Ðä´éËÂØ´ 1.> ¼èҵѴ´èǹäËÁ? ——> ¶éÒÃÍäÁèä´é ÍÒ¨äÁèÁÕàÇÅÒ bridge ——> ¶éÒÃÍä´é ¨ÐÁÕàÇÅÒ bridge 2.> ¼èҵѴãËèËÃ×ͼèҵѴàÅç¡? —> ¼èҵѴãËè ÁÕ high bleeding risk -> ¤ÇÃËÂØ´ÂÒ Keep INR < 1.5 —> ¼èҵѴàÅç¡ ÁÕ low bleeding risk -> äÁèµéͧËÂØ´ÂÒ 3.> ¨Ð Bridging äËÁ? (¡Ã³ÕËÂØ´ÂÒ ¶éÒäÁèËÂØ´ÂÒ¡çäÁèµéͧ bridge ÊÔ) —> ´Ù TE risk ¶éÒ high TE risk -> Bridge --> Low TE risk äÁèµéͧ Bridge ÊÃØ»¤×Í Emergency -> ¶éÒ¼èÒãËèµéͧ reverse ´éÇ FFP, Vitamin K IV ¡è͹ ****Vit K IV äÁè¤ÇÃãªé㹤¹ä¢é·ÕèÁÕ mechanical prosthesis Minor operation -> äÁèËÂØ´ÂÒ ¨º ¼èÒä»àÅ Major operation -> ËÂØ´ÂÒ 5 Çѹ -> ¾Ô¨ÒÃ³Ò risk TE ÀÒ¾ÃÇÁ¢Í§¡Òà Bridging warfarin ¡µÑÇÍÂèÒ§ elective major surgery ¹Ñ´ãËé¼Ùé»èÇÂËÂØ´ÂÒàͧ¡è͹¼èҵѴ 5 Çѹ ¹Ñ´ãËé¼Ùé»èÇÂÁÒ admit ËÅѧËÂØ´ÂÒä´é 2 Çѹ à¾×èÍàÃÔèÁ start LMWH àÁ×èÍ INR < 2.0 ËÂØ´ LMWH ¡è͹·ÓËѵ¶¡Òà 12 hours à¨ÒÐ INR ¶éÒ INR > 1.5 ãËé Vitamin K 1-2.5 mg reverse ËÅѧ¼èҵѴ¶éÒäÁè bleed ãËéàÃÔèÁ Warfarin + LMWH ã¹ 12-24 hours ãËé warfarin ä»àÃ×èÍÂæ ¨Ð off LMWH µèÍàÁ×èÍ INR à¢éÒ range 2 ÇѹµÔ´ à»ç¹Íѹ¨º¡Òà Bridging ( Dose : LMWH 1.5 mg/kg SC OD, LMWH 1 mg/kg SC bid)
————————————————————————— ————————————————————————— Warfarin ¤×ÍÂÒµéÒ¹¡ÒÃá¢ç§µÑǢͧàÅ×Í´ à»ç¹ VKA ËÃ×Í Vitamin K antagonist ¡Å䡤×Í ã¹¢ºÇ¹¡Ò÷ÓãËéàÅ×Í´á¢ç§µÑÇ Warfarin ¨Ðµéҹķ¸Ôì¢Í§ vitamin K «Öè§à»ç¹ cofactor ·ÕèÊÓ¤Ñ㹡Òà activate clotting factor 2,7,9,10 ·Ñé§ã¹ extrinsic pathway áÅÐ
common pathway Warfarin ¨Ðä»Ãº¡Ç¹ Vitamin K epoxide reductase â´Â enzyme ¹ÕéÁÕ˹éÒ·Õè reduct vitamin K ãËé¡ÅÒÂà»ç¹ Reduced vitamin K «Öè§ Reduced vitamin K ¹Õéà»ç¹ cofactor ¢Í§ Vitamin K dependent carboxylase ·Õè¨Ð·Ó»¯Ô¡ÔÃÔÂÒ
carboxylation hypofunctional Factor 2,7,9,10 ãËé¡ÅÒÂà»ç¹ functional Factor 2,7,9,10 ¼Å¢Í§ Warfarin ¡ç¤×ͨзÓãËéÁÕ functional factor 2,7,9,10 Ŵŧ¹Ñè¹àͧ â´ÂàÁ×èÍàÃÒãËéÂÒ warfarin à¢éÒ仹Ñ鹨ÐÊÒÁÒöŴ»ÃÔÁÒ³ clotting factor ä´é 30-50% àÅ·Õà´ÕÂÇ áµè¨ÐÊÒÁÒöŴä´é੾ÒÐ clotting factor ·ÕèÂѧäÁè¶Ù¡ÊÃéÒ§¢Öé¹à·èÒ¹Ñé¹ clotting
factor ·ÕèäËÅàÇÕ¹㹡ÃÐáÊàÅ×Í´ÍÂÙèáÅéÇ¡è͹ä´éÃѺÂÒ ¨ÐäÁèä´éÃѺ¼ÅÍÐäÃàÅ (à¾ÃÒÐÊÃéÒ§ÁÒáÅéÇ) àÃÒ¨Ö§µéͧãËéÂÒ 7-10 Çѹ¶Ö§¨ÐàÃÔèÁàË繼ŢͧÂÒ
·Õèãªé¢Í§ÂÒ warfarin ¤×Í > ãªé㹡ÒÃÃÑ¡ÉÒáÅлéͧ¡Ñ¹ PE, DVT > ãªé㹡Òûéͧ¡Ñ¹ Thromboembolic phenomenon ã¹ —> ¼Ùé»èÇ·Õè on mechanical valve —> ¼Ùé»èÇ post MI ·ÕèÁÕ indication —> ¼Ùé»èÇ atrial fibrillation —> ¼Ùé»èÇÂâäàÅ×Í´ºÒ§ª¹Ô´àªè¹ protein C, protein S deficiency
Warfarin µéͧÃÐÇѧÍѹµÃÒÂ㹡ÒÃãªéà¾ÃÒÐÁÕ therapeutic index ᤺ ¤×ͪèǧ¡ÒÃÃÑ¡ÉÒ᤺ÁÒ¡ ¹éÍÂ仡çäÁèä´é»ÃÐ⪹ì Áҡ仡çàÊÕè§ÍѹµÃÒ µéͧ»ÃѺÂÒãËé¾ÍàËÁÒÐ( therapeutic dose )
¡ÒõԴµÒÁÃдѺÂÒàÃÒ¨Ðãªé¤èÒ INR (International Normalized Ratio) «Ö觤ӹdz¨Ò¡ PT ¢Í§¼Ùé»èÇÂà·Õº¡Ñº mean PT ¢Í§»ÃЪҡà áµèÅÐ condition ·ÕèàÃÒ¨ÐÃÑ¡ÉÒ¨ÐÁÕ¡Òà keep INR goal ·ÕèµèÒ§¡Ñ¹ ÊèǹÁÒ¡¨Ð keep »ÃÐÁÒ³ 2.0-3.0 ¶éÒËÒ¡ INR<2.0 ¨ÐÁÕ¤ÇÒÁàÊÕè§µèÍ¡ÒÃà¡Ô´ ÅÔèÁàÅ×Í´ÁÒ¡ äÁèä´é»ÃÐ⪹ì¨Ò¡ÂÒ ¶éÒËÒ¡ INR>3.0 ¨ÐÁÕ¤ÇÒÁàÊÕè§µèÍ¡ÒÃà¡Ô´àÅ×Í´ÍÍ¡ÁÒ¡ ·ÕèÊӤѤ×Í intracranial hemorrhage
´Ñ§¹Ñ鹤ÇûÃѺÂÒ warfarin ãËéàËÁÒÐÊÁ à¾ÃÒÐwarfarin»ÃѺÂÒ¡ à¹×èͧ¨Ò¡ ÁջѨ¨ÑÂËÅÒÂÍÂèÒ§·Õè·ÓãËéÁѹá¡Çè§ ÁÕ·Ñé§·Õè·ÓãËé INR ÊÙ§¢Öé¹ áÅзÕè·ÓãËé INR µèÓŧ
“ÍÒËÒÔ-- à»ç¹ÊÔè§·ÕèÊÓ¤ÑÁÒ¡ â´Â੾ÒÐÍÒËÒ÷ÕèÁÕ vitamin K ÊÙ§ ¤×;ǡ¼Ñ¡ãºà¢ÕÂÇ ¤Ð¹éÒ ¼Ñ¡â¢Á ¡ÃÐËÅèÓ»ÅÕ »ÇÂàÅé§ ¨Ðä»Å´Ä·¸Ôì¢Í§ warfarin ä´é áµèäÁèãªèÇèÒäÁèãËé¡Ô¹àÅ ËÅÑ¡·ÕèÊӤѤ×ÍÊÒÁÒö·Ò¹¼Ñ¡·Ò¹ä´éàËÁ×͹à´ÔÁ áµè¾ÂÒÂÒÁ·Ò¹ã¹»ÃÔÁÒ³à·èÒæ à´ÔÁ ÍÂèÒ·Ò¹ÁÒ¡à¡Ô¹¡Çèҵ͹ªèǧ»ÃѺÂÒadvice ¼Ùé»èÇÂàÊÁÍÇèÒãËé
·Ò¹ÍÒËÒÃẺà´ÔÁ·Õèà¤Â·Ò¹ §´´×èÁáÍÅ¡ÍÎÍÅÅì §´ÊÙººØËÃÕè ã¹¢³Ð·ÕèâÊÁ (Ginseng) ¡ÃÐà·ÕÂÁ¨Ð·ÓãËé INR ÊÙ§¢Öé¹ ¨Ö§¤Çëѡ»ÃÐÇѵÔÍÒËÒÃàÊÃÔÁ ÊÁعä¾Ã·Õèãªé´éÇÂ
“ÂÒ”--warfarin à»ç¹ÂÒ·ÕèµéͧÁÕ metabolism ¼èÒ¹·ÕèµÑº â´Âà͹䫹ì CYP450 ¼Ùé»èÇ·Õè on warfarin ÍÂÙèÊèǹãËè¨ÐÁÕÂÒÍ×è¹·Õèµéͧ·Ò¹ÍÕ¡ËÅÒµÑÇ ÂÒµÑÇ·Õèà»ç¹ CYP inhibitor áÅÐ CYP inducer ¨ÐÊè§¼ÅÍÂèÒ§ÁÒ¡µèÍÃдѺÂÒ ·Õè¹èÒ¡ÅÑǤ×;ǡ CYP inhibitor
à¾ÃÒШзÓãËéÃдѺÂÒà¡Ô¹ àÊÕè§µèÍ¡ÒÃÁÕàÅ×Í´ÍÍ¡ÁÒ¡¢Öé¹
“âäÃèÇÁÍ×è¹æ”-- Liver failure, cirrhosis: ·ÓãËé clotting factor ÁÕŴŧ warfarin Í͡ķ¸Ôìà¾ÔèÁ¢Öé¹ Heart failure : àÅ×Í´ä»àÅÕ駵ѺŴŧ ÊÃéÒ§ clotting factor Ŵŧ áÅÐÅ´¡ÒáӨѴÂÒ warfarin ·ÓãËéÃдѺÂÒÊÙ§¢Öé¹ä´é Kidney failure : à¡ÕèÂǡѺàÃ×èͧ¡ÒâѺÂÒÍÍ¡¨Ò¡ÃèÒ§¡Ò Malnutrition/hypoalbuminemia : ã¹¼Ùé»èÇ·Õè albumin µèӨзÓãËé free form ¢Í§ warfarin à¾ÔèÁ¢Öé¹ à¾ÔèÁÃдѺÂÒ (à¾ÃÒÐ warfarin à»ç¹ highly-protein binding) “Hypermetabolic status” ä¢é hyperthyroidism infection ¨Ðà¾ÔèÁ¡Ò÷ÓÅÒ clotting factor Ä·¸Ôì¢Í§ warfarin ¨Ö§à¾ÔèÁ¢Öé¹ã¹ÀÒÇÐ stress àËÅèÒ¹Õé
à¾ÃÒЩйÑé¹ã¹¼ÙéÊÙ§ÍÒÂØ âäàÂÍÐæ ÇÒÂËÅÒÂæ ÍÂèÒ§µéͧÃÐÇѧÍÂèÒ§Áҡ㹡ÒÃãªéÂÒ ÁÕâÍ¡ÒÊ·ÕèÃдѺÂÒ¨Ðá¡Çè§ä´éÁÒ¡ ¤ÇÃãªé¢¹Ò´µèÓæ áÅÐÂÔ觤¹ä¢é·Õè critically ill ·ÕèÁҹ͹
âç¾ÂÒºÒŵéͧÁÕ¡ÒõԴµÒÁ INR ´éÇÂà¾ÃÒÐÍÒ¨á¡Çè§ä´é¨Ò¡ hypermetabolic state ————————————————————————— ¡ÒÃàÃÔèÁÂÒ ´Ù¢éÒ§µé¹ ————————————————————————— ¡ÒûÃѺÂÒãËéä´é INR goal ´Ù¢éÒ§µé¹
Drug interaction ·ÕèÊÓ¤Ñ
áºè§à»ç¹¡ÅØèÁ·Õè·ÓãËéÄ·¸Ôì¢Í§ warfarin à¾ÔèÁ¢Öé¹ËÃ×Í INR ÊÙ§¢Öé¹áÅÐ¡ÅØèÁ·Õè·ÓãËéÄ·¸ÔìŴŧ ËÃ×Í INR Ŵŧ INR à¾ÔèÁ¢Öé¹ (¡ÅØèÁ¹Õé¹èÒ¡ÅÑÇà¾ÃÒШзÓãËé bleed) Analgesics : Paracetamol, NSAIDs, Tramadol Cardiovascular : Amiodarone, Statin, Propanolol Antibiotics : Macrolides, FQs, Metronidazole, Bactrim Antifungals : Azoles group Acid suppression : PPIs, Cimetidine NSAIDS : -coxib, -xicam ÊÃØ»¤×;ǡ ATB: FQs, Azoles, Macrolides, MetronidazoleµéͧÃÐÁÑ´ÃÐÇѧ¡ÒÃãªé
¡ÅØèÁÂÒá¡é»Ç´·Ø¡¡ÅØèÁ Paracetamol, NSAIDS, Tramadol ÃÐÇѧINR Ŵŧ (¡ÅØèÁ¹ÕéäÁè¹èÒ¡ÅÑÇ à¾ÃÒÐá¤è¨Ð·ÓãËéäÁè¶Ö§ range §èÒÂæ) Rifampin, Griseofulvin Carbamazepine, Phenytoin Phenobarbital Cigarettes smoking Cholestyramine Sucralfate ————————————————————————— Peri-operartive warfarin management ´Ù¢éÒ§µé¹ —————————————————————————
> ¢éÍ»¯ÔºÑµÔËÒ¡Å×ÁÃѺ»ÃзҹÂÒ ËéÒÁ·Ò¹ÂÒ·º¡Ñ¹ 2 àÁç´à´ç´¢Ò´!! ËéÒÁ»ÃѺÂÒàͧ ¶éÒÅ×Á·Ò¹ÂÒ ÂѧäÁè¶Ö§ 12 ªÑèÇâÁ§ ËÃ×ͤÃÖè§Çѹ ãËéÃѺ»Ãзҹ¢¹Ò´à´ÔÁ·Ñ¹·Õ ¶éÒÅ×Á·Ò¹ÂÒ à¡Ô¹ 12 ªÑèÇâÁ§ä»áÅéÇ ãËé¢éÒÁÂÒÁ×é͹Ñé¹àÅ áÅéÇÃÍ·Ò¹Á×éͶѴä»ã¹¢¹Ò´à·èÒà´ÔÁ >ÍѹµÃ¡ÃÔÂÒÃÐËÇèÒ§ÂÒ ÍÒËÒÃàÊÃÔÁ áÅÐÊÁعä¾Ã ÍÒËÒ÷ÕèÁռŠà¹×èͧ¨Ò¡ÁջѨ¨ÑÂËÅÒÂÍÂèÒ§·ÕèÁռŵèÍÃдѺÂÒ ¤ÇÃÃÐÁÑ´ÃÐÇѧâ´Â੾ÒÐ ÍÒËÒà ÂÒ áÅÐÊÁعä¾Ã·Õèãªé ÍÒËÒÃàÊÃÔÁ·Õè¤ÇÃÃÐÇѧ àªè¹ Vitamin E, Fish oil, Gingko biloba (á»Ð¡êÇÂ) , Ginseng (âÊÁ) ÂÒÊÁعä¾ÃµèÒ§æ ¤ÇÃËÅÕ¡àÅÕè§ãªé ÍÒËÒÃàÊÃÔÁ¾Ç¡ ¼Ñ¡Ê¡Ñ´ÍÑ´àÁç´ ¤ÅÍâÿÔÅ´ìÍÑ´àÁç´ ªÒà¢ÕÂÇ ¹éÓÁѹ»ÅÒ ÇÔµÒÁԹढ¹Ò´ÊÙ§ CoQ10 ¾Ç¡ÂÒÅÙ¡¡Å͹ àÅÔ¡ alcohol áÅÐ smoking
> ¡ÒÃà¡çºÃÑ¡ÉÒÂÒ à¡çºãËé¾é¹áʧᴴáÅФÇÒÁª×é¹ à¡çºÂÒãËé¾é¹Á×Íà´ç¡ ¤ÇÃà¡çºäÇéã¹ÀÒª¹Ð·Õèâç¾ÂÒºÒŨѴãËé äÁè¤ÇÃàÍҨѴãÊè¡Åèͧ¾ÅÒʵԡ·Õè«×éÍÁÒàͧ
> ÊѧࡵÍÒ¡ÒüԴ»¡µÔ ÍÒ¡ÒÃàÅ×Í´ÍÍ¡ ¨Ø´¨éÓàÅ×Í´µÒÁ¼ÔÇ˹ѧ ¶èÒÂ´Ó ¶èÒÂà»ç¹àÅ×Í´ ÍÒà¨Õ¹à»ç¹àÅ×Í´ àÅ×Í´ÍÍ¡µÒÁäÿѹÁÒ¡¢Öé¹ »ÃШÓà´×͹ÁÒÁÒ¡ »ÑÊÊÒÇÐà»ç¹àÅ×Í´ ¶éÒÁÕÍÒ¡ÒÃàÅ×Í´ÍÍ¡·Õèã´¡çµÒÁ
ãËéËÂØ´ÂÒ áÅéÇÃÕºÁÒâç¾ÂÒºÒÅ ---------------------------------------------------------------------------------------------- ¢ÍÍÀÑ·Õè¨Ó·ÕèÁҢͧµé¹©ºÑºäÁèä´é ËÒ¡áÇмèÒ¹ÁÒàË繪èÇÂá¨é§äÇé´éǤÃѺ
Create Date : 23 ÁÕ¹Ò¤Á 2561 | | |
Last Update : 23 ÁÕ¹Ò¤Á 2561 10:29:37 ¹. |
Counter : 3792 Pageviews. |
| |
|
|
|